Market closedNon-fractional
Karyopharm Therapeutics/KPTI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
Ticker
KPTI
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Newton, United States
Employees
325
Website
www.karyopharm.com
KPTI Metrics
BasicAdvanced
$120M
Market cap
-
P/E ratio
-$1.28
EPS
0.25
Beta
-
Dividend rate
Price and volume
Market cap
$120M
Beta
0.25
Financial strength
Current ratio
3.036
Quick ratio
2.75
Long term debt to equity
-180.811
Total debt to equity
-182.839
Interest coverage (TTM)
-5.53%
Management effectiveness
Return on assets (TTM)
-31.21%
Return on equity (TTM)
136.68%
Valuation
Price to revenue (TTM)
0.784
Price to book
-0.66
Price to tangible book (TTM)
-0.66
Price to free cash flow (TTM)
-0.936
Growth
Revenue change (TTM)
-5.16%
Earnings per share change (TTM)
-26.66%
3-year revenue growth (CAGR)
7.46%
3-year earnings per share growth (CAGR)
-22.32%
What the Analysts think about KPTI
Analyst Ratings
Majority rating from 7 analysts.
KPTI Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$33M
-1.78%
Net income
-$37M
-10.77%
Profit margin
-112.68%
-9.15%
KPTI Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.29
-$0.30
-$0.36
-$0.32
-
Expected
-$0.34
-$0.28
-$0.31
-$0.33
-$0.31
Surprise
-15.26%
7.14%
16.24%
-4.15%
-
KPTI News
AllArticlesVideos
XPOVIO® (selinexor) Approved for New Indication in DLBCL in China, Bringing a New Treatment Option to Patients in the Country
PRNewsWire·3 weeks ago
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PRNewsWire·4 weeks ago
Antengene Announces XPOVIO® (selinexor) National Health Insurance Service Approval for Reimbursement in South Korea
PRNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Karyopharm Therapeutics stock?
Karyopharm Therapeutics (KPTI) has a market cap of $120M as of July 26, 2024.
What is the P/E ratio for Karyopharm Therapeutics stock?
The price to earnings (P/E) ratio for Karyopharm Therapeutics (KPTI) stock is 0 as of July 26, 2024.
Does Karyopharm Therapeutics stock pay dividends?
No, Karyopharm Therapeutics (KPTI) stock does not pay dividends to its shareholders as of July 26, 2024.
When is the next Karyopharm Therapeutics dividend payment date?
Karyopharm Therapeutics (KPTI) stock does not pay dividends to its shareholders.
What is the beta indicator for Karyopharm Therapeutics?
Karyopharm Therapeutics (KPTI) has a beta rating of 0.25. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Karyopharm Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.